All In Biotech

NDA 019071 · Mission Pharma

Urocit-K

Potassium Citrate · Oral

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 10, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Aug 30, 1985

Approved uses

1

Original approval plus efficacy supplements

Registered trials

90

16 Phase 3, 5 recruiting

FAERS reports

5,569

3,307 serious, 320 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 16, 2025.

1 INDICATIONS AND USAGE 1.1 Renal Tubular Acidosis (RTA) with Calcium Stones Potassium Citrate is indicated for the management of renal tubular acidosis [see Clinical Studies (14.1)]. 1.2 Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology Potassium Citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis [see Clinical Studies (14.2)]. 1.3 Uric Acid Lithiasis with or without Calcium Stones Potassium Citrate is indicated for the management of Uric acid lithiasis with or without calcium stones [see Clinical Studies (14.3)]. Potassium Citrate is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3)

Mechanism: When Potassium Citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, Potassium Citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. The increased filtered load of citrate may play some role, however, as in small comparisons of oral citrate and oral bicarbonate, citrate had a...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 30, 1985 Original approval · Type 3 - New Dosage Form · priority review
3 products under this application
  • UROCIT-K · POTASSIUM CITRATE 10MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • UROCIT-K · POTASSIUM CITRATE 15MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • UROCIT-K · POTASSIUM CITRATE 5MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Urocit-K" as an intervention, any sponsor and status, largest first.

All 90 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective462
  • fatigue378
  • nausea340
  • diarrhoea339
  • pain309
  • nephrolithiasis279
  • off label use271
  • dizziness248
  • dyspnoea229
  • headache217
  • fall207
  • vomiting186

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200416
200517
200626
200734
200835
200957
201078
2011104
2012112
2013123
2014145
2015290
2016365
2017326
2018374
2019373
2020409
2021449
2022516
2023450
2024446
2025484
2026340

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Urocit-K (Potassium Citrate)

2024 spending

$95K

Beneficiaries

78

274 claims

Per beneficiary

$1,212

$2.28 per unit

View as table
YearSpending
2020$256,481
2021$196,461
2022$146,317
2023$112,862
2024$94,509

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Mission Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.